Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2809562rdf:typepubmed:Citationlld:pubmed
pubmed-article:2809562lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2809562lifeskim:mentionsumls-concept:C0024117lld:lifeskim
pubmed-article:2809562lifeskim:mentionsumls-concept:C0006280lld:lifeskim
pubmed-article:2809562lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:2809562lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:2809562lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:2809562lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:2809562lifeskim:mentionsumls-concept:C0449774lld:lifeskim
pubmed-article:2809562pubmed:issue7lld:pubmed
pubmed-article:2809562pubmed:dateCreated1989-12-19lld:pubmed
pubmed-article:2809562pubmed:abstractTextTo investigate the response pattern of patients with chronic airway obstruction (CAO) to bronchodilators, 128 subjects consisting of 80 men and 48 women with a mean age of 52.6 years were randomly tested with three inhalant bronchodilators: a non-selective beta-agonist (isoproterenol), a beta 2-selective agonist (terbutaline) and an anticholinergics (ipratropium) plus placebo. All patients had a baseline FEV/FVC of less than 65% and their clinical diagnosis were classified as either COPD or bronchial asthma according to the criteria of the ACCP-ATS Joint Committee on Pulmonary Nomenclature. The drugs were delivered to the patient via a metered dose inhaler (MDI) using the conventional inhalation technique. Spirometry was measured at regular intervals with a computerized pulmonary function analyzer CHESTAC-65(Japan). A more than 15% increase in FEV1 and/or FVC after treatment was regarded as responsive. While 108 patients were tested with a single drug, the remaining 20 patients were tested sequentially with terbutaline, ipratropium and placebo in a randomized cross-over manner for studying additivity. Our results showed that the response rates of asthmatic patients to isoproterenol, terbutaline and ipratropium were 50%, 87% and 67%, respectively. Only 27% of COPD patients responded to isoproterenol and 60% to terbutaline. On the other hand, ipratropium possessed a 61% response rate in the treatment of COPD and showed a bronchodilator effect independent to that of terbutaline. Combined use of both drugs resulted in additional improvement. Once patients responded to the drugs, apparent changes in FEV1 and/or FVC occurred within 30 minutes and reached the maximum usually at 60 minutes post-inhalation.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:2809562pubmed:languageenglld:pubmed
pubmed-article:2809562pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2809562pubmed:citationSubsetIMlld:pubmed
pubmed-article:2809562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2809562pubmed:statusMEDLINElld:pubmed
pubmed-article:2809562pubmed:monthJullld:pubmed
pubmed-article:2809562pubmed:issn0371-7682lld:pubmed
pubmed-article:2809562pubmed:authorpubmed-author:WuM CMClld:pubmed
pubmed-article:2809562pubmed:authorpubmed-author:YangS CSClld:pubmed
pubmed-article:2809562pubmed:issnTypePrintlld:pubmed
pubmed-article:2809562pubmed:volume88lld:pubmed
pubmed-article:2809562pubmed:ownerNLMlld:pubmed
pubmed-article:2809562pubmed:authorsCompleteYlld:pubmed
pubmed-article:2809562pubmed:pagination700-6lld:pubmed
pubmed-article:2809562pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2809562pubmed:meshHeadingpubmed-meshheading:2809562-...lld:pubmed
pubmed-article:2809562pubmed:meshHeadingpubmed-meshheading:2809562-...lld:pubmed
pubmed-article:2809562pubmed:meshHeadingpubmed-meshheading:2809562-...lld:pubmed
pubmed-article:2809562pubmed:meshHeadingpubmed-meshheading:2809562-...lld:pubmed
pubmed-article:2809562pubmed:meshHeadingpubmed-meshheading:2809562-...lld:pubmed
pubmed-article:2809562pubmed:meshHeadingpubmed-meshheading:2809562-...lld:pubmed
pubmed-article:2809562pubmed:meshHeadingpubmed-meshheading:2809562-...lld:pubmed
pubmed-article:2809562pubmed:meshHeadingpubmed-meshheading:2809562-...lld:pubmed
pubmed-article:2809562pubmed:meshHeadingpubmed-meshheading:2809562-...lld:pubmed
pubmed-article:2809562pubmed:meshHeadingpubmed-meshheading:2809562-...lld:pubmed
pubmed-article:2809562pubmed:year1989lld:pubmed
pubmed-article:2809562pubmed:articleTitleThe response pattern of patients with chronic airway obstruction to bronchodilators.lld:pubmed
pubmed-article:2809562pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2809562pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2809562pubmed:publicationTypeRandomized Controlled Triallld:pubmed